Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06416319
Other study ID # 2021-677
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 14, 2023
Est. completion date March 14, 2026

Study information

Verified date May 2024
Source Universitätsmedizin Mannheim
Contact Karl-Friedrich Kowalewski, PD Dr. med.
Phone 0152-53404943
Email karl-friedrich.kowalewski@umm.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A bicentric, open-label randomised controlled trial (RCT) is planned to investigate whether the use of fitness wristbands in a defined preoperative period prior to radical cystectomy leads to a preoperative increase in participants' physical activity (number of steps per day) up to the day of radical cystectomy.


Description:

The goal of the PreAct study is to test whether the use of fitness wristbands in a defined preoperative period prior to radical cystectomy with a daily activity goal and feedback on the achievement of this goal improves the participants' physical activity up to the day of radical cystectomy. In addition to the fitness tracker, we provide each patient with a smartphone. For each fitness tracker a separate account in a fitness application is set up for (e.g. name: tracker1.0 with the corresponding e-mail address and password). Neither the patients in the Daily activity Goal and Feedback arm nor the No Daily Activity Goal or Feedback arm receive the access data to the accounts. However, the patients in the intervention group receive the access PIN for the smartphone. On this smartphone a messaging service and the fitness application are installed. The patient thus receives, for example the wristband tracker1.0, which is registered with the corresponding access data in the fitness application of the smartphone given to them. For the entire preoperative period, the Bluetooth function on the smartphone must always stay activated so that the fitness application and the fitness tracker are continuously connected to each other. A detailed description of the timing and implementation of the intervention are described in "Study design" and "Arm and Interventions".


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date March 14, 2026
Est. primary completion date March 14, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Planned radical cystectomy with bilateral pelvic lymphadenectomy and one of the different forms of urinary diversion (continent vs. incontinent; orthotopic vs. heterotopic) in patients with bladder cancer - Participants age = 18 years and capacity to consent - Mobile participant who is not dependent on a walking aid - The participant declares his or her consent to participate in this study by signing and dating the informed consent form prior to the surgical procedure Exclusion Criteria: - Karnofsky performance status scale = 70% (with 70%: Care for self. Unable to carry on normal activity or to do active work (Ambulatory and capable of all selfcare but unable to carry out any work activities). ) (Range: 0 - 100 percent with 0 percent "participant´s death" and 100 percent "no disabilities" - ASA Physical Status Classification: ASA > 3 (3: A patient with severe systemic disease) - ASA 1, 2, 3 if acute or chronic diseases of the musculoskeletal system or the central nervous system are involved that result in a symptomatic restriction of motor and / or, in the last case, neurological function (healing ruptures and fractures, Parkinson's disease, multiple sclerosis, etc.) - Emergency intervention

Study Design


Intervention

Device:
Daily Activity Goal and Feedback
The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.

Locations

Country Name City State
Germany Department of Urology, University Medical Center Mannheim, University of Heidelberg Mannheim Baden-Württemberg
Germany Urologische Klinik München Planegg (UKMP) München Bayern

Sponsors (2)

Lead Sponsor Collaborator
Universitätsmedizin Mannheim Dr. Rolf M. Schwiete Foundation

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of steps per day Average daily step count measured by the fitness tracker during the period of prehabilitation 7 to 10 days before surgery. Participants' daily step count is recorded on the day of surgery when the fitness tracker is put down.
Secondary Total number of steps Total number of steps measured by the fitness tracker during the period of prehabilitation 7 to 10 days before surgery. Participants' total number of steps is recorded on the day of surgery when the fitness tracker is put down.
Secondary Postoperative physical activity The postoperative physical activity of the participants measured by the average number of steps per day and in total on postoperative days 1 to 3. Neither arm will receive a daily activity goal. However, the fitness trackers of the No Daily Activity Goal or Feedback arm are still covered. Morning of postoperative day 4 at 7 PM
Secondary Postoperative Complications Postoperative complications measured by the Comprehensive Classification Index (CCI), on a scale from 0 (no complications) to 100 (death), (Slankamenac, Graf et al. 2013) and the Clavien-Dindo Classification (CDC), which consists of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V), the first one indicating any deviation from the normal postoperative course, the highest grade indicating death (Clavien, Barkun et al. 2009):
CDC = 3a corresponding to a CCI = 26.2 defined as "severe complications" including CDC = 5 and CCI = 100 defined as "patient's death" and the total number of complications
On postoperative day 30 and 90
Secondary Operating time In minutes, incision - surgical incision closure On the day of surgery
Secondary Blod loss In millilitres On the day of surgery
Secondary Required transfusion of blood products Number of red blood cell concentrates, platelet concentrates, frozen fresh plasma On the day of surgery
Secondary Feasibility of the planned urinary diversion Yes or no On the day of surgery
Secondary Conversion rate If the planned urinary diversion is not feasible On the day of surgery
Secondary Patient Reported Outcome Measures (PROMs) SF-36: Health-related quality of life (Scale 0 - 100: The higher the score, the lower the disability. A score of 100 corresponds to no disability) On the day of randomization at the premedication appointment and on the day of discharge which is on average 2 weeks after the surgery and postoperative day 30 and 90
Secondary Length of hospital stay (LOS) LOS measured by the number of days spent in the hospital after surgery until discharge On the day of discharge which is on average 2 weeks after the surgery
Secondary Readmission rate Readmissions due to a complication of the radical cystectomy On postoperative day 90 if occured
Secondary Reoperation rate Reoperation due to a complication of the radical cystectomy On postoperative day 90 if occured
Secondary Length of stay in the intensive care unit (ICU) Days spent in the ICU after surgery On postoperative day 90 if occured
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A